A recent meta-analysis by Giugliano et al. provided an update of all large CV outcome trials (CVOTs) with SGLT-2 inhibitors, with findings indicating that treatment with SGLT-2 inhibitors in patients with T2DM resulted in a sustained to moderate reduction of the composite CV death or hospitalization for HF, robust reduction of HF, moderate reduction of CV mortality, total mortality and major adverse cardiac events (MACE) [66]. This evidence concerns the gene SLC5A2 and hydrops fetalis.